[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"childhood-malignant-solid-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:childhood-malignant-solid-neoplasm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053903","quality-of-end-of-life-care-for-children-with-cancer-100053903",false,"NCT07412002","Quality of End-of-Life Care for Children With Cancer","Quality of End-of-Life Care for Children With Cancer: A COG Groupwide Observational Study","Inclusion Criteria:\n\n* Index Child (COG Registered Patient):\n\n  * Must be deceased\n  * \\\u003C 18 years old at time of death\n  * Diagnosed with any oncologic condition\n  * History of enrollment on Stratum 1 of APEC14B1, Project:EveryChild\n\n    * Note: history of treatment on a COG therapeutic trial is not required\n  * Resided in the United States, including Puerto Rico, as evidenced by most recent address, at the time of death\n\nBereaved Parent(s):\n\n* Must be a parent, legal guardian, or caregiver (biological or non-biological) of an eligible Index Child enrolled on APEC14B1 with current Consent to Future Contact (e.g., from the APEC14B1 Part B Consent)\n* Self-reported confirmation of familiarity with the care received by the Index Child in the last month of their life\n* Bereaved parent must understand English or Spanish (written and\u002For spoken)\n* Must be a parent\u002Fguardian\u002Fkey contact from the Index Child's APEC14B1 Future Contact study record or must be referred by one of the APEC14B1 contacts\n* Bereaved parent must be \\>= 18 years old at the time of ALTE24C1 study enrollment\n\nRegulatory Requirements:\n\n* Bereaved parent must provide verbal or implied informed consent\n* For all participants, all institutional, FDA, and NCI requirements for human studies must be met",true,"ALL","18 Years",{"count":20,"type":21},2425,"ESTIMATED","OBSERVATIONAL","This study examines the role of access to care, patient\u002Ffamily interactions with the healthcare system, and stress in explaining variations in quality of end of life care. The data collected from this study may help researchers develop a model for identifying patients at risk of low quality end of life care as well as recommendations for potential future interventions.",[25,26],"Childhood Hematopoietic and Lymphatic System Neoplasm","Childhood Malignant Solid Neoplasm","RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2026-06-15",{"date":35,"type":21},"2031-01-31",{"name":37,"class":38},"Children's Oncology Group","NETWORK",13,{"id":41,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":42,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":44,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":48,"completionDateStruct":49,"leadSponsor":50,"locationsCount":51},"100624620",{"count":43,"type":21},1190,[25,26],"2026-06-25",{"date":47,"type":31},"2026-06-29",{"date":33,"type":31},{"date":35,"type":21},{"name":37,"class":38},2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100586465","phase-3-an-imaging-agent-pafolacianine-for-identifying-lesions-in-pediatric-patients-with-primary-or-metastatic-solid-tumors-100586465","NCT06915727","An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors","Pafolacianine for Localization of Pediatric Extracranial Solid Tumors","Inclusion Criteria:\n\n* Willingness of research participant or legal guardian\u002Frepresentative to give written informed consent\n* Age 6 months to 17 years\n* Have a diagnosis, or a high clinical suspicion, of a solid tumor in the neck, chest, abdomen, pelvis, or extremities with a plan for surgical resection including embryonal tumors, sarcomas, neurogenic tumors, carcinomas, mesenchymal tumors, germ cell tumors. Children may undergo surgical resection or biopsy of a solid tumor that is suspected to be malignant without a separate preoperative biopsy; therefore, the tumor type may not be definitively known preoperatively\n\nExclusion Criteria:\n\n* Previous exposure to Cytalux™ (pafolacianine) injection\n* Any medical condition that in the judgement of the investigators could potentially jeopardize the safety of the participant\n* History of anaphylactic reactions to products containing indocyanine green for near infrared imaging. Participants with a medical history of 'idiopathic anaphylaxis' will require evaluation\n* History of allergy to any of the components of Cytalux™ (pafolacianine) injection\n* Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule\n* Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to the administration of the study drug. Investigational trials involving administration of drugs or vaccines which are already Food and Drug Administration (FDA)-approved, such as Children's Oncology Group cooperative trials, are okay\n* Known sensitivity to fluorescent light\n* Pregnancy\n* Unable or unwilling to discontinue folic acid, folate supplements, and multi-vitamins containing folate 48 hours prior to drug administration\n* Renal failure on dialysis or estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.72m\\^2 as measured by the U25 eGFR equation for patients ≥1 year(s) of age. For patients \\\u003C 1 year of age, creatinine \\> 2x the upper limit of normal will serve as an exclusion criteria. Creatinine will be measured by enzymatic assay with calibration traceable to the international standard reference materials and minimal bias compared to isotope-dilution mass spectrometry (IDMS) reference methodology.\n* Undergoing workup for liver failure or listed for liver transplant. Patients with Gilbert's syndrome will be excluded if impaired liver function defined as values \\> 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin\n* Unable or unwilling to use adequate birth control\u002Fcontraceptive measures or abstain from sexual activity for 30 days following the study intervention\n* Anticipated need to donate ova or sperm within 30 days following study intervention","6 Months","17 Years",{"count":62,"type":21},20,"INTERVENTIONAL",[65],"PHASE3","This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Pafolacianine is a fluorescent imaging agent that targets folate receptors which are overexpressed in many cancers and is used with near infrared (NIR) imaging during surgery to identify tumor cells. NIR uses a special camera that uses wavelengths in the infrared range to visualize and locate the tumor cells that are lit up by the pafolacianine. Giving pafolacianine for NIR imaging may work better than other imaging agents in identifying cancerous lesions in pediatric patients with solid tumors.",[26,68,69,70,71,72],"Childhood Malignant Thoracic Neoplasm","Malignant Abdominal Neoplasm","Malignant Neck Neoplasm","Malignant Pelvic Neoplasm","Metastatic Childhood Malignant Solid Neoplasm","2026-03-27",{"date":75,"type":31},"2026-04-01",{"date":77,"type":31},"2025-04-15",{"date":79,"type":21},"2027-05-01",{"name":81,"class":82},"Mayo Clinic","OTHER",1]